… A retrospective cohort study of 88 NSCLC patients with EGFR mutation positive treated
with gefitinib (n=59), erlotinib (n=22), and afatinib (n=7) was performed in national cancer …

… This is the first large cohort study of real-world performance of first-line gefitinib, erlotinib
and afatinib chosen by clinicians in a freely competitive manner. This is also the first report to …

… This is a retrospective study of a prospectively maintained cohort. The aims of this study were
to compare the efficacy among three first-generation EGFR-TKIs as adjuvant treatment and …

… 17.3 months for gefitinib, 12.4 months for erlotinib, and 23.3 … –0.83) compared with gefitinib
or erlotinib. In the competing … failure compared with gefitinib or erlotinib after adjusting for both …

… A retrospective cohort study of Chinese patients with metastatic NSCLC harboring EGFR
mutations who received first-line gefitinib, erlotinib or afatinib treatment, followed by osimertinib …

… The slightly higher T790M yield of both the gefitinib/erlotinib and afatinib groups in the
present study might be related to the addition of a liquid biopsy when a tissue biopsy was …

… This retrospective cohort study was conducted using data from real-world settings. Patients
with stage IIIB and IV NSCLC and first received gefitinib, erlotinib, or afatinib between 2011 …

… erlotinib, we observed a poorer adjusted survival for gefitinib … , this study is the largest
European real-world cohort of … erlotinib, we observed a poorer adjusted survival for gefitinib …

… -based cohort study demonstrated that concurrent PPI with gefitinib or erlotinib was
associated with significantly poorer OS and TTNT than the H2RA and non-user. Other studies …

… Eligible patients with indication of gefitinib treatment were prospectively enrolled in this
study. Two peripheral blood samples at baseline and before cycle 2 day 1 were collected for the …